1235406-63-9Relevant academic research and scientific papers
The discovery and evaluation of diaryl ether heterocyclic sulfonamides as URAT1 inhibitors for the treatment of gout
Storer, R. Ian,Owen, Robert M.,Pike, Andy,Benn, Caroline L.,Armstrong, Emma,Blakemore, David C.,Bictash, Magda,Costelloe, Kathryn,Impey, Emma,Milliken, Philip H.,Mortimer-Cassen, Elisabeth,Pearce, Hannah J.,Pibworth, Benjamin,Toschi, Gianna
, p. 1587 - 1595 (2016)
Elevated serum uric acid levels can lead to gout which remains an area of unmet medical need. Following an unexpected clinical uricosuric effect observed with a sulfonamide compound, PF-05089771 (9), subsequently attributed to weak URAT1 inhibition, the o
SULFONAMIDES DERIVATIVES AS URAT1 INHIBITORS
-
, (2016/03/19)
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a sulfonamide URAT1inhibitor of formula (I), or a pharmaceutically acceptable salt thereof for use as a medicament, wherein R1, X1 and m as defined in the description, and to certain new sulfonamide URAT1 inhibitors. URAT1 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly gout.
CHEMICAL COMPOUNDS
-
Paragraph 0412; 0413; 0414; 0415, (2014/10/29)
The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes, and
